ARDX News and Press, Ardelyx Inc. From 04/25/22

What to Know About Buying Penny Stocks on April 25th With another day of trading penny stocks here, there is a lot for investors to consider. Now, with so much going on in the stock market in the past few months, investors should be used to a high level of volatility. [Read More] ...

Ardelyx (NASDAQ:ARDX) has added ~43% in the pre-market Monday after the Waltham, Massachusetts-based biotech announced that the FDA plans to conduct an AdCom meeting regarding its marketing application for kidney disease drug, XPHOZAH (tenapanor). Last year, the FDA declined to appr...

Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor) PR Newswire - Ardelyx welcomes the opportunity for the company, patients, and practicing nephrologists to speak to clinically meaningful results in treating hyperphosphatem...

Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor PR Newswire WALTHAM, Mass. , April 11, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative fi...

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings PR Newswire Four posters support the important role that XPHOZAH, with its novel phosphate blocking mechanis...

3 Hot Biotech Penny Stocks to Add to Your April 2022 Watchlist There are many different stocks to choose from when investing looking for biotech penny stocks. As with any investment, you want to find stocks that are doing well and have a good track record of performance and growth. This...

Ardelyx [[ARDX, +15%]] on Monday announced the U.S. launch of Ibsrela to treat irritable bowel syndrome with constipation (IBS-C) in adults. Ardelyx (NASDAQ:ARDX) President and CEO Mike Raab said Ibsrela is the first novel mechanism therapy to be introduced for IBS-C in ov...

Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults PR Newswire IBSRELA ® (tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in Adults First Novel Mechanism ...

StoneCo (STNE) +29% on Q4 results. Kidpik (PIK) +22%. Sunshine Biopharma (SBFM) +16%. Yumanity Therapeutics (YMTX) +12%. On Holding (ONON) +9% on Q4 results. Hycroft Mining Holding (HYMC) +9%. PagSeguro Digital (PAGS) +8%. Houston American Energy (HUSA) +8%. Zhihu (ZH) +8%...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...